KDC-MN-249 – Kodiac biolabs

Plain-language summaryIntrigue 47 / 100

Tandospirone (Sediel, Senparen) is a Japanese-developed second-generation azapirone from Sumitomo, approved in Japan in 1996 and China in 2004. It has not been pursued in Western markets. Mechanistically it is closely related to buspirone, partially activating the serotonin 5-HT1A receptor, but with somewhat higher intrinsic activity at the receptor (around 60 percent versus buspirone’s 35 percent). Used for generalized anxiety and adjustment disorders, with some research interest in cognitive effects through 5-HT1A in the prefrontal cortex. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished workhorse

31/100

A mature azapirone 5-HT1A partial agonist with narrow bench utility as a buspirone comparator

Look, tandospirone is a perfectly competent azapirone. Developed at Sumitomo, approved in Japan in 1996 and China in 2004, it does what the class does: partial agonism at 5-HT1A with a binding affinity around 27 nM and intrinsic activity in the 60 percent range. That last number is actually the most interesting thing about it. Buspirone, the dominant Western reference azapirone, sits closer to 40-45 percent intrinsic activity, so tandospirone offers a way to ask whether higher partial agonism translates to meaningfully better anxiolytic or antidepressant signal in a head-to-head experimental setup. Thats a real, answerable question.

The problem is that the question isnt very exciting anymore. 5-HT1A partial agonism has been studied relentlessly since buspirone hit the US market in 1986, and the clinical returns across the azapirone class have been modest. GAD is a genuine indication, but nothing in this receptor corner has broken out into something field-defining. Tandospirone’s clinical literature is almost entirely Japanese and Chinese, peer-reviewed but difficult to replicate in Western contexts, and the mechanistic work points back to the same receptor biology the field has understood for decades. The evidence base is real; it’s just mature.

Sourcing outside Japan and China is genuinely awkward. It’s not a Western research staple, which means the research-grade supply chain is thin compared to buspirone. We’ve seen this pattern with other Asian-market approvals where Western labs end up defaulting to the more available analog because sourcing friction outweighs the marginal mechanistic difference. The active metabolite 1-PP is also shared across azapirones, which can muddy interpretation when you’re trying to attribute effects specifically to the parent compound versus class-level pharmacology.

What we think: tandospirone has a narrow legitimate use case as a reference compound when 5-HT1A intrinsic activity gradations genuinely matter to your experimental design. If you’re constructing a dose-response curve across the partial agonism range and need something between buspirone and a full agonist, tandospirone fills that slot. But thats a specific niche, not a broad research program. The compound isn’t overhyped, it isn’t disproven, it just lives in a thoroughly mapped mechanistic corner of psychiatric pharmacology. For investigators interested in the serotonin receptor landscape from a fresh angle, the multi-target profile of something like vortioxetine or the ongoing work in 5-HT2A/1A crosstalk around psychoplastogens is where the real action is right now. Tandospirone belongs where the numbers put it: a serviceable reference tool in a class that ran out of frontier a long time ago.

Novelty: 22
Mechanism promise: 22
In-category differentiation: 28
Evidence quality: 48
Translational signal: 42
Research bench value: 35

Rationale Tandospirone is a 30-year-old Asian-market anxiolytic in a thoroughly characterized receptor class; its only differentiating feature is marginally higher 5-HT1A intrinsic activity than buspirone, giving it a narrow reference-tool use case but no serious novelty or mechanistic frontier value. Evidence is real but geographically concentrated and non-paradigm-shifting, placing it firmly in piracetam territory on the overall scale.

5-HT1A partial agonist anxiolytic (Asian markets)

A second-generation azapirone 5-HT1A partial agonist marketed in Japan and China; not approved in Western markets.

Abstract

Tandospirone ((1R,2R,6S,7S)-4-(4-{[4-(pyrimidin-2-yl)piperazin-1-yl]butyl})-4-azatricyclo[5.2.1.02,6]decane-3,5-dione; CAS 87760-53-0; molecular formula C21H29N5O2; molecular weight 383.49) is a second-generation azapirone 5-HT1A partial agonist developed at Sumitomo and approved in Japan in 1996 (Sediel) and China in 2004 (Senparen). Receptor profile is closely related to buspirone: 5-HT1A affinity approximately 27 nM (intrinsic activity approximately 60 percent, higher than buspirone); minimal D2 affinity. Compared to buspirone, the higher 5-HT1A intrinsic activity is hypothesized to produce somewhat greater anxiolytic and antidepressant effect. Plasma half-life is approximately 1 hour; metabolism is via CYP3A4 with active metabolite 1-PP common to the azapirone class. Approved indications include generalized anxiety disorder and adjustment disorder with anxiety; off-label use in depression. Not approved in the US or EU. Used as a reference azapirone with higher 5-HT1A intrinsic activity than buspirone in mechanism studies.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-249Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

Tag: KDC-MN-249

Tandospirone

Abstract

Read the full monograph